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Proteotranscriptomic Profiling of 231-BR
Breast Cancer Cells: Identification of Potential
Biomarkers and Therapeutic Targets for Brain
Metastasis*□S
Matthew D. Dun‡§‡‡, Robert J. Chalkley¶‡‡, Sam Faulkner‡§, Sheridan Keene‡§,
Kelly A. Avery-Kiejda‡§, Rodney J. Scott‡§, Lasse G. Falkenby, Murray J. Cairns‡§,
Martin R. Larsen, Ralph A. Bradshaw¶, and Hubert Hondermarck‡§**
Brain metastases are a devastating consequence of can-
cer and currently there are no specific biomarkers or
therapeutic targets for risk prediction, diagnosis, and
treatment. Here the proteome of the brain metastatic
breast cancer cell line 231-BR has been compared with
that of the parental cell line MDA-MB-231, which is also
metastatic but has no organ selectivity. Using SILAC and
nanoLC-MS/MS, 1957 proteins were identified in recipro-
cal labeling experiments and 1584 were quantified in the
two cell lines. A total of 152 proteins were confidently
determined to be up- or down-regulated by more than
twofold in 231-BR. Of note, 112/152 proteins were de-
creased as compared with only 40/152 that were in-
creased, suggesting that down-regulation of specific pro-
teins is an important part of the mechanism underlying the
ability of breast cancer cells to metastasize to the brain.
When matched against transcriptomic data, 43% of indi-
vidual protein changes were associated with correspond-
ing changes in mRNA, indicating that the transcript level
is a limited predictor of protein level. In addition, differen-
tial miRNA analyses showed that most miRNA changes in
231-BR were up- (36/45) as compared with down-regula-
tions (9/45). Pathway analysis revealed that proteome
changes were mostly related to cell signaling and cell
cycle, metabolism and extracellular matrix remodeling.
The major protein changes in 231-BR were confirmed by
parallel reaction monitoring mass spectrometry and con-
sisted in increases (by more than fivefold) in the matrix
metalloproteinase-1, ephrin-B1, stomatin, myc target-1,
and decreases (by more than 10-fold) in transglutaminase-2,
the S100 calcium-binding protein A4, and L-plastin. The clin-
icopathological significance of these major proteomic
changes to predict the occurrence of brain metastases, and
their potential value as therapeutic targets, warrants further
investigation. Molecular & Cellular Proteomics 14: 10.1074/
mcp.M114.046110, 2316–2330, 2015.
Brain metastases affect 10–20% of cancer patients with
disseminated disease (1). Even small lesions can cause neu-
rological disability, and the median survival time of patients
with brain metastases is short, with about 80% mortality
within one year of diagnosis. The molecular basis of cancer
metastases to the brain remains unknown and with advances
in the control of systemic disease, the incidence of brain
metastases is increasing (1, 2). In the case of breast cancer,
brain relapse typically occurs years after primary tumor exci-
sion, suggesting that disseminated breast cancer cells must
first acquire specialized functions to invade and grow in this
organ (3). Retrospective studies of breast cancer patients with
brain metastases found that a young age at diagnosis, pri-
mary tumors that are estrogen receptor negative or overex-
pressing the human epidermal growth factor receptor 2
(HER2)1 and/or epidermal growth factor receptor, and the
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presence of lymph node or distant metastases were all asso-
ciated with a higher risk of brain metastatic disease (4). How-
ever, at this stage there is no molecular marker, at the gene,
mRNA or protein level that is clinically useful to predict, diag-
nose, or treat breast cancer-derived brain metastases (5).
Therefore it is essential to better define the molecular basis for
these phenomena and delineate predictive biomarkers and
therapeutic targets for future innovative treatments.
In the present study, proteome changes associated to brain
metastatic capabilities of breast cancer cells were explored.
To that purpose, we have used the unique opportunity pro-
vided by the 231-BR/MDA-MB-231 cellular models. 231-BR
cells (also named MDA-MB-231BR) have initially been estab-
lished from the triple negative (no expression of estrogen
receptor, progesterone receptor, and HER2) MDA-MB-231
cells, which are highly metastatic but have no organ specific-
ity, being able to metastasize to many different sites. The
brain metastatic 231-BR cell line has been derived from MDA-
MB-231 cells after successive rounds of implantation, resec-
tion from the brain, and re-injection into mice, to produce a
subline with selectivity for the brain as compared with other
metastatic sites (6). 231-BR cells metastasize with 100%
frequency to the brain and they have progressively emerged
as an established preclinical model of brain metastatic breast
cancer (2). For instance, they have been used to demonstrate
that Her-2 overexpression increases the metastatic outgrowth
of breast cancer cells in the brain (7), that the anti-HER2 drug
lapatinib can inhibit the growth of brain metastatic cells (8),
and that the blood–tumor barrier permeability determines
drug efficacy in experimental brain metastases (9). They have
also been used to analyze brain metastasis in magnetic res-
onance imaging (10) and to investigate brain damage induced
by brain metastases (11).
Despite the considerable interest and use of 231-BR cells
for studying the mechanisms underlying brain metastasis, the
proteome of these cells has not been thoroughly explored.
One study (12) has reported a 2D electrophoresis-based anal-
ysis, but no major proteome changes were identified. In the
present report, stable isotope labeling of amino acids in cul-
ture (SILAC) and liquid chromatography (LC)-MS/MS tandem
mass spectrometry was used to analyze the proteome of
231-BR versus MDA-MB-231 cells. Changes in the proteome
were compared with those in the transcriptome (mRNA and
miRNA), and several proteins and molecular pathways that
may participate in the underlying basis of metastasis to the
brain have been identified.
EXPERIMENTAL PROCEDURES
The workflow of this study is presented in Fig. 1. Institutional Ethics
Committee approval was obtained from the University of Newcastle
Australia.
Cell Culture and SILAC Labeling—Breast cancer cell lines 231-BR
and parental MDA-MB-231 were a generous gift from Dr. Patricia S.
Steeg (National Cancer Institute, Bethesda, MD). Both cell lines were
routinely grown in DMEM supplemented with 2 mM L-glutamine and
10% fetal calf serum (Sigma-Aldrich, St. Louis, MO) in 75 cm2 tissue
culture flasks in a humidified incubator at 37 °C with 5% CO2. 231-BR
and MDA-MB-231 cells were reciprocally labeled using SILAC heavy
13C6-lysine (Lys6) and L-arginine-HCl (Arg0), labels dissolved in SILAC
RPMI 1640 medium without arginine and lysine and supplemented
with 10% dialyzed fetal bovine serum (Pierce SILAC Protein Quanti-
tation Kit, Rockford, IL). Light condition medium was supplemented
with L-lysine 2HCl (Lys0) L-arginine HCl (Arg0). The concentrations of
supplemented amino acids used were 50 mg/L. The cells were pas-
saged seven times with intermediate splitting after 3 days and at a
density of 5  105 cells/75-cm flask. Cells were counted and pelleted
at 1 107 cells and snap frozen in liquid nitrogen. Reciprocal labeling
provides a biological replicate, as two different sets of cell cultures
are used for protein preparation before independent analyses by
mass spectrometry. Specifically, there were two biological replicates
for 231-BR cells (13C6 L-Lysine labeled-Heavy and
12C6 L-Lysine
labeled-Light), and two biological replicates for MDA-MB-231 (13C6
L-Lysine labeled-Heavy and 12C6 L-Lysine labeled- Light). For mass
spectrometric analyses (13C6 L-Lysine labeled-Heavy) 231-BR were
analyzed versus (12C6 L-Lysine labeled-Light) MDA-MB-231), and
(12C6 L-Lysine labeled-Light) 231-BR versus (
13C6 L-Lysine labeled-
Heavy) MDA-MB-231. The final results correspond to the mean of the
two mass spectrometric analyses.
Protein Preparation for Mass Spectrometry—Membrane proteins
were enriched from the soluble proteins of the SILAC heavy and light
reciprocally labeled 231-BR and MDA-MB-231 cell pellets and unla-
beled cell pellets for label-free parallel reaction monitoring (PRM)
analysis (1 107 cells) by dissolving each cell pellet in 1 ml of ice-cold
0.1 M Na2CO3 supplemented with protease inhibitor (Roche Complete
EDTA Free), sonicated for 2  20 s and incubated for 1 h at 4 °C. The
homogenates were then centrifuged at 100,000 g for 90 min at 4 °C
(13). The membrane pellets were redissolved in 500 mM triethylam-
FIG. 1. Experimental workflow. Stable isotope labeling of amino
acids in cell culture (SILAC) reciprocal labeling was performed on
both the brain metastatic breast cancer cell line 231-BR and the
parental cell line MDA-MB-231, which is also metastatic but has no
organ selectivity. After extraction, mixing 1:1, and protein digestion
with trypsin, LC-MS/MS analysis (using a Q-Exactive Plus from
Thermo Fischer Scientific after liquid chromatography on a Nano-
Acquity ultraperformance column from Waters) was used to identify
and quantify reciprocally labeled proteins. Peptide sequence, protein
identification, and quantification were obtained using Protein Pro-
spector and the SwissProt database. Major protein changes ob-
served in SILAC were validated in parallel reaction monitoring (PRM)
from nonlabeled proteins. Protein pathway analysis was performed
with Ingenuity Pathway Analysis software. In parallel to proteomics, a
transcriptomic analysis was conducted. mRNA and miRNA were ex-
tracted from both cell lines (three biological replicates). GeneChip
Exon arrays analysis and GeneChip miRNA arrays were used for
analyzing the expression of mRNA and miRNA respectively.
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monium bicarbonate and centrifuged at 14,000 g for 30 min at 4 °C.
These pellets were then briefly rinsed in 50 mM triethylammonium
bicarbonate and stored on ice. Soluble proteins were concentrated
(Microcon-10kDa Centrifugal Filter Unit, Millipore, Billerica, MA) and
both the pellets and concentrated soluble proteins dissolved in urea
buffer (6 M urea, 2 M thiourea) and reduced using 10 mM dithiotreitol
(1 h, 56 °C), alkylated using 20 mM iodoacetamide (45 min, room
temperature, in the dark), and subsequently digested with 0.05 activ-
ity units of Lys-C endoproteinase (Wako, Osaka, Japan) for 3 h at
37 °C. After Lys-C digestion, the solution was diluted below 0.75 M
urea, 0.25 M thiourea, and digested with 2% w/w trypsin (Promega,
Madison, WI) overnight at 37 °C. Each peptide sample was desalted
using a modified StageTip microcolumn (14) consisting of a pipette tip
with a C18 Empore disk plug packed with Poros Oligo R3 reversed
phase material. Peptides were acidified (pH 2) using 10% trifluoro-
acetic acid (TFA) and loaded on the Oligo R3 microcolumn. The
microcolumn was washed with 0.1% TFA, and the peptides were
eluted sequentially with 50% acetonitrile, 0.1% TFA then 70% ace-
tonitrile, 0.1% TFA. The eluents were lyophilized.
LC-MS/MS for SILAC Analyses—Mass spectrometry was per-
formed using a Q-Exactive Plus (Thermo Fisher Scientific). Chroma-
tography was performed using a NanoAcquity ultraperformance liquid
chromatography system (Waters, Milford, MA) at a flow rate of 400
nl/min using a EASY-Spray PepMap C18 75 m  150 mm column
(Thermo), with a 240-min gradient. Solvent A was water, 0.1% formic
acid, and solvent B was acetonitrile, 0.1% formic acid; peptides were
eluted by a gradient from 2 to 28% solvent B from 20 to 215 min, then
28 to 40% B over a further 5 mins, before returning to the starting
conditions. After a precursor scan of intact peptides was measured in
the Orbitrap by scanning from m/z 350–1500 (with a resolution of
70,000), the ten most intense multiply charged precursors were se-
lected for higher energy collision-induced dissociation fragmentation
with a normalized collision energy of 30.0, then measured in the
Orbitrap at a resolution of 17,500. Automatic gain control targets were
3E6 ions for Orbitrap scans and 50,000 for MS/MS scans. Dynamic
exclusion was employed for 15 s. SILAC labeling efficiency was
determined using MS/MS spectra. The mean labeling efficiency
between reciprocal experiments was calculated at 92%. The raw
data has been uploaded to the MassIVE public repository:
ftp://MSV000078911@massive.ucsd.edu.
Peptide and Protein Identification—Fragmentation data were con-
verted to peak lists using an in-house script based on the Raw_
Extract script in Xcalibur version 2.4 (Thermo Fisher Scientific), and
the higher energy collision-induced dissociation data for each sample
were searched using Protein Prospector version 5.10.15 (15) against
all human entries in SwissProt (downloaded June 27, 2013, with a
total of 20,265 entries), to which a randomized version of all entries
had been concatenated. The following search parameters were used:
mass tolerances in MS and MS/MS modes were 10 ppm and 20 ppm,
respectively; trypsin was designated as the digestion enzyme, and up
to two missed cleavages were allowed; S-carbamidomethylation of
cysteine residues was designated as a fixed modification; variable
modifications considered were protein N-terminal acetylation, N-ter-
minal glutamine conversion to pyroglutamate, methionine oxidation
and 13C6-labeled lysine. Results from searches of membrane and
soluble fractions were merged into a single results file using Search
Compare. Results were thresholded at an estimated 1% false discov-
ery rate (FDR) at the protein level (peptide-level FDR was around
0.1%) according to concatenated database search results (16). An-
notated spectra can be viewed using MS-Viewer (http://prospector2.
ucsf.edu/prospector/cgi-bin/msform.cgi?formmsviewer) (17) using
the following search keys: Biological Repeat 1 - p2iuesahfg; Biolog-
ical Repeat 2 (reciprocal labeling) - lzcne57i8x.
Protein Quantification Using SILAC—SILAC quantification mea-
surements were extracted from the raw data by Search Compare in
Protein Prospector. Search Compare averaged together MS scans
from10 s to20 s from the time at which the MS/MS spectrum was
acquired to produce measurements averaged over the elution of the
peptide. Search Compare calculates a noise level in the averaged
spectrum. Only peaks with a signal to noise of greater than 10 were
used in quantification measurements. The raw data has been up-
loaded to the MassIVE public repository: ftp://MSV000078911@
massive.ucsd.edu. If one of the SILAC pair is above this threshold and
the other is below, then the ratio is reported with a  or  (see raw
data for SILAC), indicating one value was below the noise level, so the
ratio reported is a minimum estimate. The standard deviation of the
log ratios for peptides matched to the same protein (where all ratios
should be the same) was 0.11. The twofold threshold change em-
ployed as significant therefore corresponds to 2.74 (log(2)/0.11)
standard deviations from the mean. Assuming a Gaussian distribution,
this threshold would correspond to a 99.4% confidence threshold that
a twofold difference is nonrandom. This corresponds to a 0.6% FDR.
Furthermore it is necessary to emphasize here that multiple testing
adjustment is not required in this study, as we are only testing one
hypothesis; that protein x is changing in abundance in one cellular
model. For these calculations the fact that one protein changes or not
does not affect the probability of another protein changing.
PRM Mass Spectrometry—PRM was used to confirm the major
protein changes in 231-BR versus MDA-MB-231 cells (proteins up-
regulated by more than fivefold and down-regulated more than 10-
fold) observed in the SILAC analyses. Peptides were extracted from
231-BR and MDA-MD-231 cells as described above (see Protein
preparation for mass spectrometry) but from a different batch of
cultured cells (biological replicate). These peptides were loaded on
C18-containing stage tips prior to reversed phase chromatography on
a SPE-LC (modified EASY-nLC 1000, Thermo, Odense, Denmark), as
described in Falkenby et al. (77). Short gradients ranging from 4 to
35% in 5 min were used. In-house prepared 6 cm columns with pulled
emitter and ReproSil-Pur 120 C18-AQ 3 m material (Dr Maisch,
Germany) were used in combination with a nano-ESI source
(Proxeon, Odense, Denmark). PRM was performed using a Q Exactive
mass spectrometer (Thermo Scientific, Bremen, Germany). Methods
optimized for collision energy, charge state, and retention times for
the most significantly regulated peptides were generated experimen-
tally using two unique peptides of high intensity and confidence for
each target protein. Targeted MS2 spectra were acquired using a
PRM approach (18) at a resolution of 35,000, employing a high AGC
target value of 3e6 ions and a maximum injection time of 100 ms.
Scheduled acquisition in windows of up to 1 min was used to limit the
number of concurrent targets to a maximum of four. The raw data
has been uploaded to the MassIVE public repository: ftp://
MSV000078911@massive.ucsd.edu. These data were analyzed using
Skyline (MacCoss Lab, University of Washington) (19) where signal
intensities for individual peptide sequences for each of the signifi-
cantly altered proteins were quantified relative to each sample and
normalized to heat shock 60kDa protein 1 (chaperonin, HSPD1) that
was found to be homogeneously expressed in each cell type (pep-
tides for HSPD1 were optimized and shown to be high intensity and
confident transitions). Quantification was performed by measuring the
extracted ion chromatogram for each transition for each peptide in
triplicate LC MS/MS runs and results were compared between cell
types using a Student’s t test.
Exon-based Microarray Analysis of mRNA Expression—Isolation of
RNA was performed from three biological replicates of 231-BR and
MDA-MB-231 cells using the illustra RNAspin Mini Isolation Kit (GE
Healthcare) according to the manufacturer’s instructions (protocol
25–0500-70PC). The RNA concentration was measured using Nano-
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photometer (Implen, Munchen, Germany) and the quality was deter-
mined using Agilent 2100 Bioanalyser (Agilent Technologies, Santa
Clara, CA). Microarray analysis of mRNA expression was performed
at the Australian Genome Research Facility (AGRF, Melbourne, Aus-
tralia). Briefly, a total of 3 g was labeled using the Affymetrix WT
cDNA Amplification kit (Millenium Science, Mulgrave, Australia). The
subsequent cRNA was cleaned using the Affymetrix GeneChip Sam-
ple Cleanup kit (Millenium Sciences). Upon cleaning of the cRNA,
dUTP was incorporated into the second cycle of the first strand cDNA
synthesis step. The presence of the dUTP was used to facilitate
fragmentation using the APE1 and UDG enzymes that specifically
recognized dUTP. The fragmented cDNA was quality checked using
the Agilent Bioanalyser 2100 with the NanoChip protocol. The frag-
mented single stranded cDNA was end-labeled using terminal deoxy-
nucleotidyl transferase and the WT Terminal Labeling kit (Millenium
Sciences). A total of 5 g of labeled cDNA for each of the three
biological replicates of 231-BR versus MDA-MB-231 was then hybrid-
ized to the HumanExon 1.0 ST Array GeneChip (Millenium Sciences)
by preparing a probe mixture (labeled cDNA at 0.025 g/ul) that
includes 1 hybridization buffer (100 mM MES, 1 mM NaCl, 20 mM
EDTA, 0.01% Tween-20), 0.1 mg/ml herring sperm DNA, 0.5 mg/ml
BSA, and 7% DMSO. A total hybridization volume of 220 l was
prepared for each sample and 200 l loaded into a HumanExon 1.0
ST Array GeneChip. The chip was hybridized at 45 °C for 16 h in an
oven with a rotating wheel at 60 rpm. After hybridization the chip was
washed using the appropriate fluidics script in the Affymetrix Fluidics
Station 450. Upon completion of the washing, the chips are then
scanned using the Affymetrix GeneChip Scanner 3000. The scanner
operating software, GCOS, converts the signal on the chip into a DAT
file, which was used for generating the subsequent CEL file for
analysis. The ratio of gene expression in 231-BR versus MDA-MB-231
cells was derived from Cel files, but is presented in terms of % of
increase/decrease. The raw data has been uploaded to the MassIVE
public repository: ftp://MSV000078911@massive.ucsd.edu. The data
from each array was imported into Genespring GX v 12.1 (Agilent
Technologies) as CEL files and robust multi-array analysis was used
to log-transform, background-correct, quantile normalize, and sum-
marize the probe features resulting in a set of expression signal
intensities. The signal intensities were baseline transformed to the
median signal intensity of all arrays. Unpaired moderated t tests were
used to identify genes with significantly altered expression (twofold,
p  0.05). To correct for false positive results, a Benjamini and
Hochberg FDR of 5.0% was used for multiple testing.
MicroRNA Expression Profiling—Isolation of microRNA (miRNA)
from three biological replicates of 231-BR and MDA-MB-231 cells
was performed using the mirVana miRNA isolation kit (Life Technol-
ogies) according to the manufacturer’s instructions (protocol 1560 M
Rev. C). The RNA concentration was determined using a Nanopho-
tometer (Implen) and the quality was determined using Agilent 2100
Bioanalyser (Agilent Technologies). Total RNA (1 g) from each rep-
licate was biotinylated using the FlashTag Biotin HSR kit (Genisphere,
Hatfield, PA) in triplicate according to the manufacturers’ instructions
(protocol 877.888.3DNA). Labeled RNA was hybridized to GeneChip
miRNA-2 arrays (Affymetrix, Santa Clara, CA) for 16 h before washing
and staining the arrays using the GeneChip Hybridization (Affymetrix),
Wash and Stain kit according to the manufacturers’ instructions (pro-
tocol P/N 702731 Rev. 3). Arrays were scanned on a GeneChip®
Scanner 3000 7G (Affymetrix). Analysis GeneChip miRNA-2 arrays
contain 15,644 probe features representing 1105 unique human ma-
ture miRNAs, 1105 unique human pre-miRNAs and 2334 human
snoRNA and scaRNAs (Affymetrix). The data from each array was
imported into Genespring GX v 12.1 (Agilent Technologies) and robust
multi-array analysis was used to log-transform, background-correct,
quantile normalize, and summarize the probe features resulting in a
set of expression signal intensities. The signal intensities were then
baseline transformed to the median signal intensity of all arrays.
Unpaired moderated t tests were used to identify miRNAs with sig-
nificantly altered expression (2-fold, p  0.05). To correct for false
positive results, a Benjamini and Hochberg FDR of 5.0% was used for
multiple testing. Supervised hierarchical cluster analysis was per-
formed on miRNAs that were found to be significantly different (2
fold, p  0.05, FDR0.05). Similarity in the average expression pat-
terns between miRNAs was measured by Euclidian’s distance. The
raw data has been uploaded to the MassIVE public repository: ftp://
MSV000078911@massive.ucsd.edu. Biological targets of differen-
tially expressed miRNAs were identified by searching for the presence
of conserved eight-mer and seven-mer sites within genes that match
the seed region of each miRNA. For miRNA families, conservation
cutoffs were defined as described by Friedman et al. (20) as follows:
broadly conserved (conserved across most vertebrates, usually to
zebrafish); conserved (conserved across most mammals, but usually
not beyond placental mammals), or poorly conserved (all others). For
human miRNA, site conservation were defined by conserved branch
length, with each site type having a different threshold for conserva-
tion: eight-mer   0.8; seven-mer-m8   1.3; seven-mer-1A  
1.6 as defined (20). The data were searched for miRNA potential
targets using sRNA Target Base (starBase, http://starbase.sysu.
edu.cn) (21), which integrates data from 21 Ago or TNRC6 CLIP-Seq
sequence data sets with the target prediction programs Target Scan,
Pictar and miRanda. The analysis was performed as previously de-
scribed (22) and miRNA that were validated by all three target-pre-
diction algorithms, and for which confidence is therefore high, have
been selected.
Molecular Pathway Analysis—SILAC data was analyzed using Qia-
gen Ingenuity Pathway Analysis (IPA®, Qiagen Redwood city, CA,
www.qiagen.com/ingenuity). Proteins showing differential regulation
(at least twofold expression changes) were uploaded and networks
were generated using data sets containing gene identifiers and their
corresponding expression values. Networks of these focus genes
were then algorithmically generated based on their connectivity using
stringent human filter options describing molecules and relationships.
Graphical networks depicting significant activation or inhibition of
molecular pathways were generated. Pathways with a p value 0.05
were considered to be significantly regulated. The p value0.05 was
used to identify pathways in the study that might explain the changes
of protein expression observed between 231-BR and MDA-MD-231
cells. It suggests a statistically significant link between proteins show-
ing significant regulation and genes that are regulated by a known
transcription regulator. It was calculated, as part of Ingenuity Pathway
analysis process, using Fisher’s Exact Test (significance of the asso-
ciation or contingency test).
RESULTS
Proteome Profiling of 231-BR versus MDA-MB-231 Cells—
Using SILAC based LC-MS/MS analysis of 231-BR and MDA-
MB-231 cells, 2266 and 2434 proteins, respectively, were
identified in reciprocal labeling experiments. Together, 1957
proteins were reciprocally identified and 1584 were quantified
in both experiments. A total of 152 proteins, representing
9.6% of all quantified proteins, were found to be regulated by
at least twofold in 231-BR as compared with MDA-MB-231,
with 40 up- and 112 down-regulations (Fig. 2A). The correla-
tion plot of changes in protein quantification obtained in the two
replicates of the SILAC analysis is presented (Fig. 2B). The
Pearson coefficient of correlation (R square) was 0.66 (p 
0.0001), demonstrating the reliability of the list of regulated
Proteotranscriptomics of Brain Metastatic Breast Cancer Cells
Molecular & Cellular Proteomics 14.9 2319
FIG. 2. Distribution of protein, mRNA, miRNA changes in 231-BR compared with MDA-MB-231. A, The level of 1584 proteins were
compared between 231-BR and MDA-MB-231 cells and 152 were found regulated by more than twofold (112 decreased and 40 increased).
The number of proteins (y axis) is in Log scale. B, Correlation plot between SILAC replicates. Changes in protein levels obtained in replicate
1 versus replicate 2 are presented. The x and y axes are in Log scale. The Pearson correlation coefficient (R square) was 0.66 (p  0.0001).
C, 22,011 mRNA were quantified in 231-BR versus and MDA-MB-231. Three hundred and six mRNA were significantly regulated by at least
twofold (70 decreased and 226 increased). D, Correlation plot between protein and mRNA level changes. The mRNA change was plotted for
the 152 protein changes in 231-BR. The Pearson correlation coefficient (R square) was 0.67 (p  0.0001). E, 1105 miRNA were quantified in
231-BR versus MDA-MB-231 and 45 were found regulated by at least twofold. Nine miRNA were decreased and 36 increased in 231-BR cells.
F, Correlation plot between miRNA and their predicted protein targets. The Pearson correlation coefficient (R square) was 0.37 (p  0.0459).
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proteins. The characteristics (gene and protein name, accession
number, number of unique peptides, protein fold changes, best
peptide E-values, mRNA fold changes, and associated nominal
p values) of the 152 proteins differentially regulated between
231-BR and MDA-MB-231 are shown in supplemental Table
S1. For mRNA, test adjustments (Bonferroni, sidak, q-value) are
in the raw data accessible on line (MassIVE public repository:
ftp://MSV000078911@massive.ucsd.edu). Analysis of the local-
ization (Fig. 3A and 3B) and function (Fig. 3C and 3D) of regu-
lated proteins showed differences between up-regulated (Fig.
3A and 3C) and down-regulated (Fig. 3B and 3D) proteins.
Statistical significances were calculated using Chi-square (two-
tailed). The proportion of nuclear proteins was higher among
up-regulated (45%) than down-regulated (24%) proteins (p 
0.001) and the proportion of cytoplasmic proteins was higher in
the down-regulated proteins (56%) compared with the up-reg-
ulated proteins (40%) (p 0.023). The proportion of membrane
and extracellular proteins was not statistically different between
up- and down-regulated proteins (p  0.05). The proportion of
different functional categories of regulated proteins was differ-
ent among up- and down-regulated proteins (Fig. 3C–3D). The
proportion of proteins involved in signaling and cell cycle was
27% in the up-regulated group and 34% in the down-regulated
group (p  0.029), whereas the proportion involved in intracel-
lular trafficking was 5% in up-regulated proteins and 16% in
down-regulated proteins (p 0.011). The proportion of proteins
involved in ECM remodeling, transcription/translation, metabo-
lism, and proteins of unknown function was not statistically
different between up- and down-regulated proteins (p  0.05).
The largest proteome changes in 231-BR were increases (by
more than fivefold) in the matrix metalloproteinase MMP1, the
growth factor ephrin-B1 (EFNB1), the membrane protein STOM,
the N-acetyl-glucosamine pyrophophorylase UAP1, the target
of Myc MYCT1, and decreases (by more than 10-fold) in the
transglutaminase TGM2, the metastasis associated protein
S100A4 and the actin cross-linker LCP1 (or L-plastin). The
MS/MS spectra of the most up-regulated and down-regulated
proteins, MMP1 and TGM2, respectively, are presented in Fig.
4. Figs. 4B, 4C, 4E, and 4F demonstrate the reproducible quan-
tification results obtained between the reciprocal labeling
experiments.
PRM Analysis of the Major Protein Changes in 231-BR
versus MDA-MB-231—The major protein changes in 231-BR
(increases by more than fivefold for MMP1, EFNB1, STOM1,
UAP1, MYCT1 and decreases by more than 10-fold for TGM2,
S100A4, and LCP1) were analyzed by label-free PRM mass
spectrometry. The analysis was performed from a different set
of cell cultures than for the SILAC analyses (biological repli-
cate). Product ions of selected peptides were monitored in
parallel using one injection over a full mass range. Two unique
peptides for each protein were used for quantification. Each
PRM experiment was performed in triplicate and normalized
to control peptides revealed by SILAC based LC-MS/MS
analysis to be expressed 1:1 (HSPD1, further confirmed to be
expressed 1:1 by PRM). Peptide ratios for the label-free PRM
quantification were generated in Skyline measuring the area
FIG. 3. Distribution of proteins regulated in 231-BR cells (as compared with MDA-MB-231) in function of subcellular localization and
ontology. A, Subcellular localization of proteins showing increased expression by twofold or greater in 231-BR cells. B, Subcellular localization
of proteins showing decreased expression by twofold or greater in 231-BR cells. C, Gene ontology of proteins identified showing increased
expression by twofold or greater in 231-BR cells. D, Gene ontology analysis of proteins showing decreased expression by twofold or greater
in 231-BR cells.
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FIG. 4. LC-MS/MS based identification and quantification of MMP1 and TGM2. Matrix metalloproteinase-1 (MMP1) and transglu-
taminase-2 (TGM2) were differentially expressed between 231-BR and MDA-MB-231 cells. A, MS/MS spectrum of peptide MIAHDFP-
GIGHK from MMP1. B, Precursor intensity for this peptide in 231-BR cells is roughly 14-fold more intense than in the parent cell line, based
on SILAC labeling; C, In the reciprocal labeling experiment, the heavy precursor is now significantly more intense. D, MS/MS spectrum of
heavy-labeled peptide MDLLPLHMGLHK from TGM2. E, The light equivalent of this peptide was not detected in 231-BR sample; F, In the
reciprocal labeling experiment signal for the 231-BR sample is in the noise level of the spectrum, indicating an at least 18-fold difference
in expression level between cell lines.
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under the curve of three to eight transitions selected for each
peptide (precursor ion/product ion). These were averaged for
each protein and then compared with averaged reciprocal
SILAC quantification values. All transition ions obtained for
each of the nine analyzed proteins are presented (supplemen-
tal Table S2). The quantifications for each analyzed protein
(using two peptides/protein) in 231-BR versus MDA-MB-231
are presented (supplemental Fig. S3). The results indicate that
for 7/8 proteins analyzed, the PRM data validated the results
obtained using SILAC. The increase in MMP1, EFNB1,
STOM1, MYCT1 in 231-BR, as well as the decrease in TGM2,
S100A4, and LCP1 were confirmed by PRM. The only change
that was not confirmed by PRM was the increase in UAP1. As
shown in supplemental Fig. S3, the two peptides used for
UAP1 provided contradictory results in PRM as one showed
no change whereas the other indicated decrease in 231-BR.
In the SILAC analyses, UAP1 was characterized with only one
peptide. Therefore, change in the UAP1 level in 231-BR could
not be confirmed. A correlation curve was generated (Fig. 5)
between protein changes observed by PRM and by SILAC.
The coefficient of correlation (coefficient of determination,
R-square) was 0.86 (p  0.0003), indicating a high level of
correspondence in the results obtained by the two method-
ological approaches.
Expression of mRNA in 231-BR versus MDA-MB-231
Cells—Changes in mRNA levels in 231-BR compared with
MDA-MB-231 cells were analyzed in exon-based microarray
analysis. A total of 296 changes in individual mRNA levels of
at least twofold were observed in 231-BR (supplemental Table
S4). This included 226 up-regulations and 70 down-regula-
tions of individual mRNAs. The distribution of changes in
mRNA is reported in Fig. 2C and the relative mRNA levels for
each of the proteins regulated in the SILAC proteomics ex-
periment are reported in supplemental Table S1. Overall, only
43% of the individual changes in protein expression were
associated with corresponding changes in the transcript lev-
els. The correlation plot of changes in proteins versus mRNA
(Fig. 2D) indicated a Pearson correlation coefficient (R square)
of 0.67 (p 0.0001). This shows that alterations in mRNAs are
limited predictors of changes in the corresponding proteins,
suggesting post-transcriptional regulation. Noticeably, there
was a significant difference between up- and down-regulated
proteins in regard to changes in mRNA levels. In the case of
up-regulated proteins, 65% had a corresponding increase in
mRNA, but for down-regulated proteins a corresponding
change in mRNA level was found in only 35% of cases.
Therefore 65% of the up-regulated proteins could be related,
at least in part, to increases in mRNA level, whereas only 35%
of the down-regulated proteins were accompanied by a de-
crease in mRNA, further supporting post-transcriptional reg-
ulation as being particularly relevant to the down-regulation of
individual proteins in 231-BR.
miRNA Expression in 231-BR versus MDA-MB-231 Cells—
The level of 1105 unique mature miRNA, 1105 pre-miRNAs,
and 2334 snoRNA and scaRNAs was analyzed in 231-BR and
MDA-MB-231 cells using microarrays. A total of 45 miRNAs
were found to be differentially regulated by at least twofold in
231-BR cells (supplemental Table S5), including nine down-
regulations and 36 up-regulations (Fig. 2E). The higher pro-
portion of miRNA that were increased matched the predom-
inant down-regulation of protein levels observed in the SILAC
proteomic results (supplemental Table S1), suggesting that
miRNAs are involved in protein level changes, and in partic-
ular in the down-regulations. However, using prediction of
miRNA targets, we were able to identify only six of the pro-
teins regulated in 231-BR as potential targets of four regu-
lated miRNA (supplemental Table S6). To be more specific,
three increases in miRNA (miR-195, miR-182, miR-34a) po-
tentially corresponded to down-regulation at the protein levels
(for VAMP8, IGF2R, HDGF, ACTR2, ANLN), and 1 miRNA
decrease (miR-424–5p) corresponded to up-regulation at the
protein level (SLC4A7). Overall, five out of the 112 down-
regulated proteins were targets of certain miRNAs, whereas it
FIG. 5. Correlation plot of PRM and SILAC quantification of
protein changes in 231-BR versus MDA-MB-231 cells. The eight
proteins that were found most regulated in 231-BR compared with
MDA-MB-231 cells using SILAC-based quantification were analyzed
in a label-free quantification PRM experiment. The changes in protein
levels were confirmed in seven out of eight cases (MMP1, EFNB1,
STOM1, MYCT1, TGM2, LCP1, S100A4) in PRM. Only the change in
UAP1 level was not confirmed in PRM. Data (from PRM and SILAC)
for these proteins are plotted here. HSP1 was used as a control
unregulated protein. The axes for SILAC and PRM represent the Log
of mean ratios 231-BR/MDA-MB-231. The coefficient of linear regres-
sion (coefficient of determination, R square) between PRM and SILAC
was 0.86 (p  0.0003).
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was 1/40 for up-regulated proteins; this was not statistically
different (p  0.05 using Chi-square two-tailed). Also, the
correlation plot between changes in miRNA and their pre-
dicted protein targets (Fig. 2F) indicated a Pearson correlation
coefficient (R square) of only 0.37 (p  0.0459).
Integrated Overview of the Proteome/Transcriptome/
miRNA Changes in 231-BR versus MDA-MB-231 Cells and
Molecular Pathway Analysis—An overview of changes ob-
served at the three expression levels (protein - mRNA -
miRNA) is presented in Table I. Ingenuity pathway analysis
revealed that most proteome changes in 231-BR (Fig. 6A)
were related to cell death and survival, cell growth and differ-
entiation, cellular movement, cell cycle and cell-to-cell inter-
action. In terms of prediction of upstream regulatory path-
ways, the pathways regulated by tumor necrosis factor 
(TNF-), extracellularly regulated kinases, the histone dem-
ethylase KDM5B (Lysine (K)-Specific Demethylase 5B), the
estrogen receptor and the cyclin dependent kinase 1A
(CDKN1A) were activated in 231-BR (Fig. 6B). Significantly
inhibited pathways in 231-BR cells (Fig. 6C) were predicted to
be related to transforming growth factor  (TGF-), the E3
ubiquitin-protein ligase SYNVN1 (synovial apoptosis inhibitor
1 or synoviolin), the transcription factor FOXO1 (Forkhead box
protein O1), the receptor TREM1 (triggering receptor ex-
pressed on myeloid cells 1), and the progesterone receptor.
The TNF- and TREM1 pathways were found with 5% FDR
and p 0.05, whereas all the other pathways were found with
1% FDR and p  0.01 (Fig. 6B and 6C).
DISCUSSION
In this study, the differential protein/mRNA/miRNA content
of a brain-colonizing breast cancer cell line (231-BR) was
compared with the parental nonspecific metastatic cell line
(MDA-MB-231), with the view of determining the molecular
features that could account for the differing phenotypes of
these cells. There has already been many studies comparing
the proteome of metastatic versus nonmetastatic breast can-
cer cells (23–27); this study focused on a unique genetically
homogenous cellular model to delineate proteome changes
associated to a brain-seeking phenotype of breast cancer
cells. The seed and soil theory of metastasis that was origi-
nally established in breast cancer by Paget in 1889 (28),
described metastasis in terms of an interaction between a
tumor cell and a local environment. This concept has been
extended to other types of cancer and although it is con-
stantly revisited (29), there is an agreement that adequate
molecular determinants are necessary, on both the cancer
cells and the target organ, to permit the establishment of
metastases. The proteomic signature identified in this study
provides a framework for a better understanding of the mech-
anisms triggering brain metastasis, and for delineating future
biomarkers and therapeutic targets of clinical interest.
Overall Changes in Proteins versus mRNA and miRNA—
Comparing changes in 231-BR at the protein versus the
mRNA level indicates that only 43% of the individual protein
changes were associated with concomitant changes in the
respective mRNA. This confirms the already reported fact that
the transcript level is a limited predictor of the protein level
(30, 31). Currently, breast tumors are classified based on
transcriptomics/gene expression into four main classes: lumi-
nal A, luminal B, HER2, and triple negative; however, this
classification is constantly being refined with the addition
of new subclasses (32). The limited association between
changes at the protein versus mRNA level that are reported
herein points to the need to further explore the proteome of
breast tumors, and ultimately define the proteogenomic pro-
file of this disease. This study represents an exploratory step
in this direction. Significantly, most of the proteome changes
in 231-BR were decreases in individual protein levels (112/
152), suggesting that down-regulation of specific proteins
may be an important part of the mechanism underlying the
ability of breast cancer cells to metastasize specifically to the
brain. Alternatively, it is also possible that the proteins are
down-regulated simply because they are no longer needed in
brain metastasis and they have been selected against during
the multiple cycles of injection and recovery from the mice.
Interestingly, differential microRNA analyses indicated that
most miRNA changes in 231-BR were up-regulations (36/45),
suggesting that the trend toward protein down-regulation
could be at least partially controlled by opposite changes in
levels of regulatory miRNAs. However, target prediction of
miRNA, using three different target prediction tools, identified
only four regulated miRNA potentially corresponding to six
regulated proteins. Together, these results suggest that
changes in miRNAs are part of the molecular profile of brain
metastatic breast cancer cells, but the correlation between
specific up-regulated miRNAs, putative down-regulated pro-
tein targets and brain metastatic phenotype was not tested
experimentally. Further functional investigation will be needed
to clearly link specific changes in miRNA to changes in protein
levels.
Pathway Activation/Inactivation—It is important to empha-
size the predictive nature of pathway analysis. The pathways
presented here indicate predicted activation and inhibition of
TABLE I
Overview of proteome/mRNA/miRNA changes in 231-BR versus
MDA-MB-231.  indicates up-regulation and - indicates down-regu-
lation. FDR, false discovery rate. Cut-off values for significance were
as follows. For proteins, twofold, best E-value2.5E-05, FDR 
0.6%. For mRNA, twofold, p  0.05, FDR  5%. For miRNA,
twofold, p  0.05, FDR  5%
Regulated in 231-BR
Total numbers
quantified
- 
Proteins 112 40 1,584
mRNA 70 226 22,011
miRNA 9 36 1,105
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signaling networks based on the up- and down-regulations
determined in the SILAC analysis. However it does not con-
stitute a graphical representation of SILAC results and there is
no direct evidence in our study for those hub proteins. How-
ever, as described below, the literature indicates that these
hubs are expressed in breast cancer cells. Significantly inhib-
ited pathways in 231-BR were those related to TGF-, the E3
ubiquitin-protein ligase SYNVN1 and the transcription factor
FOXO1, whereas the pathways associated to TNF-, and the
histone demethylase KDM5B were activated. TGF- has been
shown to be produced by both glial cells and neurons, and to
participate in the development and maintenance of the brain
FIG. 6. Protein pathways regulated in 231-BR. Pathway analysis of proteins differentially regulated in 231-BR versus MB-MDA-231 was
performed using Ingenuity Pathway Analysis. A, Protein pathways activated in 231-BR were found related to cell death and survival, protein
synthesis, cell cycle, cell-to-cell interaction, and molecular transport (number of proteins for each pathway are indicated in ordinate, p values
are indicated on top of each column). B, Predicted upstream pathways activated in 231-BR. The p values for activated pathways were
CDKN1A, 4.1  105; extracellularly regulated kinases, 2.9  103; KDM5B, 7  103; TNF-, 4.3  102; ER, 2.9  103. C, Predicted
upstream pathways inhibited in 231-BR. The p values obtained for inhibited pathways were TGF-, 2.  106; SYVN1, 6.25  107; FOXO1,
4.69  107; TREM1, 3.73  102; PGR, 9.44  103. For B and C, the TNF- and TREM1 pathways were found with 5% FDR and p  0.05,
whereas all the other pathways were found with 1% FDR and p  0.01. Networks are presented in the centroid of connecting lines in bold font
with rectangle icons. Blue fill indicates a significant inhibition in the 231-BR cells and B orange indicates significant activation. Proteins are
represented by circle or oval icons with a green shading corresponding to a twofold or greater decreased expression, and a red shading
correspond to a twofold or greater increased expression in the 231-BR cells. Intensity of each color represents the level of expression. Solid
lines suggest direct interactions and dashed lines suggest indirect ones. Orange lines lead to activation and blue lines lead to inhibition. Yellow
lines are for inconsistency in state (up or down) of downstream molecule and gray are for effect yet to be predicted. Protein names are reported
in supplemental Table S1.
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microenvironment mainly through its neuroprotective effect
(33). TGF- has also been shown to inhibit the anchorage-
independent growth of 231-BR (6); therefore it is conceivable
that the down-regulation of the TGF- signaling pathway
could be a way to escape growth inhibition by TGF- normally
present in the brain microenvironment. The pathway con-
trolled by SYVN1 was also down-regulated in 231-BR. SYVN1
is involved in endoplasmic reticulum (ER)-associated degra-
dation and removes unfolded proteins accumulated during ER
stress by retrograde transport to the cytosol from the ER. This
protein also uses the ubiquitin-proteasome system for addi-
tional degradation of unfolded proteins. The potential role of
SYVN1 in carcinogenesis is, at this stage, limited to the tar-
geting of the tumor suppressor p53 for ubiquitination (34)
leading to its degradation in the cytoplasm, but it is unclear
how this relates to brain metastasis. The third down-regulated
pathway identified is related to the transcription factor
FOXO1. Suppression of FOXO1 activity has recently been
associated with increased tumorigenicity of breast cancer
cells (35) and FOXO1 is involved in the control of E2F1 tran-
scriptional specificity and apoptotic function (36). Therefore
the down-regulation of FOXO1 is coherent with increased
tumor aggressiveness and in return may also participate in the
regulation of the TGF-, MMP1, and SYVN1 pathways. In
contrast to inhibited pathways, this study also points to the
significant activation of pathways associated to TNF- and
the histone demethylase KDM5B. TNF- is a major pro-in-
flammatory cytokine involved in growth, differentiation, and
survival of many cell types. In breast cancer cells, TNF-
participates in the epithelial–mesenchymal transition pheno-
type (37) and its targeting, using blocking antibodies, sup-
presses breast cancer growth (38). Our study therefore em-
phasizes the value of targeting the TNF- pathway in breast
cancer. Similar to genetic alterations, epigenetic aberrations
contribute significantly to tumor initiation and progression.
The pathway related to the histone demethylase KDM5 was
found to be increased in 231-BR cells. The KDM5 family of
histone demethylases are capable of removing tri- and di-
methyl groups from lysine 4 on histone H3, a modification that
occurs at the start site of transcription in actively transcribed
genes (39). Preclinical studies suggest that the inhibition of
these enzymes can suppress tumorigenesis (40), and this
study points to a possible involvement in brain metastasis.
Interestingly, the pathways controlled by progesterone and
estrogen receptors were found differentially regulated, de-
spite the fact that 231-BR and MDA-MB-231 cells are triple
negative breast cancer cells that do not express these recep-
tors. However, the pathway analysis provides clues for alter-
nate regulation. Indeed, the regulation of NT5E, ITGB1, and
ITGA3, which can be controlled by ER, can also occur through
the pathways mediated by TREM1 and TGF- (as shown in
Fig. 6C). Also, the regulation of ETS1 can be induced through
the TNF- pathway (as shown in Fig. 6B). Similarly, the up-
regulation of F3 that can be controlled by PR can also be
regulated through the TNF- pathway (as shown in Fig. 6B).
Each of these alternate potential effectors (TREM1, TGF-,
and TNF-) has been identified previously in breast cancer
cells (41–43).
Proteins Up-regulated in the Brain Metastatic 231-BR
Cells—Of particular interest was the up-regulation (by 14-
fold) of the matrix metalloproteinase MMP1, which promotes
collagen degradation. MMP1 overexpression has been asso-
ciated with metastatic capacities of breast cancer cells by
favoring extracellular matrix degradation and thus facilitating
invasion and extravasation of cancer cells (44). Of note,
MMP1 expression is under the control of the transcription
factor ETS1 that was also found to be up-regulated (although
to a lesser extent than MMP1) in 231-BR. MMP1 overexpres-
sion is associated with poor patient outcome (45) and in a
mouse xenograft model it has been shown that MMP1 inhi-
bition decreases local growth and brain metastasis of breast
cancer cells (46). Therefore the results presented here confirm
the involvement of MMP1 in brain metastasis by showing its
increased protein level in 231-BR cells. A few recent studies
have suggested that MMP1 plays an important role in the
regulation of neuronal apoptosis and astrocyte proliferation
(47), suggesting that MMP1 up-regulation in breast cancer
cells could lead to a remodeling of brain extracellular matrix,
making it favorable for their implantation into the brain mi-
croenvironment. In terms of therapeutic targeting, inhibitors of
MMPs, despite considerable excitement during the last two
decades, have failed to enter the clinic because of their un-
wanted musculoskeletal side effects (48, 49) and it is therefore
unlikely that targeting MMP1 would be a viable therapeutic
option for metastatic breast cancer. Interestingly, other en-
zymes involved in extracellular matrix remodeling were also
found among the regulated proteins.
Another major change in 231-BR cells was the up-regula-
tion (by ninefold) of ephrin-B1. Ephrins are plasma mem-
brane-bound growth factors that act by stimulation of Eph
tyrosine kinase receptors on juxtaposed cells, initiating mul-
tiple intracellular phosphorylation cascades (50). The ensuing
signals are bidirectional as ephrins can also transduce signals
(known as reverse signals) following their interaction with Eph
receptors. The biological functions of ephrins range from cell
growth, adhesion, and migration to axon guidance and angio-
genesis, resulting in critical regulatory roles in embryonic de-
velopment and carcinogenesis (50). Eph receptors require
direct cell-to-cell interaction for activation and they are di-
vided into EphA and EphB receptor classes, depending on
their preferential binding affinity for ephrinA or ephrinB li-
gands. Eph receptors have been documented in cancer (51),
but the ligands have not been thoroughly investigated and in
particular there is limited data on ephrinB1. However, a recent
study has shown that enhanced expression of ephrinB1 is
associated with lymph node metastasis and poor prognosis in
breast cancer (52). The authors did not propose a mechanism
to explain the association between ephrinB1 and poor patient
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survival, but another recent study has shown that ephrinB1 is
a substrate for PTEN and interacts with the tyrosine kinase
receptor HER2 (or ErbB2) (53). Interestingly, breast tumors
overexpressing HER2 are prone to metastasize to the brain (7)
and therefore an association of HER2 with ephrinB1 could be
a driver of brain metastasis. In terms of therapeutic potential,
ephrinB1 is expressed at the cell surface and could potentially
be targeted. Although there are no inhibitors of ephrins in
clinical use, a number of peptides and chemical compounds
that target Eph receptors and inhibit ephrin binding or down-
stream kinase activation have been identified (56). These mol-
ecules show promise as probes to study Eph receptor/ephrin
biology, as lead compounds for drug development and as
targeting agents to deliver drugs or imaging agents to tumors.
The data presented herein clearly support that the potential
use of ephrin inhibitors against brain metastasis should be
further considered.
Stomatin (STOM) and MYCT1 were also found to be
strongly up-regulated (by at least fivefold) in 231-BR. Stoma-
tin is an integral membrane protein, the absence of which is
associated with a form of hemolytic anemia known as hered-
itary stomatocytosis. It is reported that stomatin regulates the
gating of acid-sensing ion channels in mammalian neurons,
but the function of stomatin is not fully understood (57).
MYCT1 (or MTMC1) is a helix-loop-helix leucine zipper tran-
scription factor, which is a direct target of c-Myc. Its overex-
pression recapitulates multiple c-Myc phenotypes, including
cell transformation (61). Deregulation of c-Myc is a hallmark of
many human cancers, as the c-Myc oncoprotein directly reg-
ulates the expression of 1500 genes controlled by RNA
polymerases I, II, and III (62). Although a role for MYCT1 in
brain metastasis has not been reported, this study suggests
that it could be related to brain metastasis.
Proteins Down-regulated in 231-BR Cells—The most dra-
matically down-regulated protein was tissue transglutaminase
TGM2, which was decreased by 50-fold in 231-BR. Inter-
estingly the mRNA of TGM2 was also strongly decreased (by
16-fold), suggesting a regulation at the transcriptional level.
TGM2 is a thiol enzyme that catalyzes a crosslinking reaction
between a specific -glutamyl containing peptide substrate
and either a -amino group from a peptide-bound Lys residue
or a free primary amine (63). These reactions result in post-
translational modifications of proteins that can alter their sol-
ubility, structure, and function. The -glutamyl- -lysine (iso-
peptide) bonds that can be catalyzed by TGM2 result in the
formation of either an inter- or intra-isopeptide bond. Many
intra- and extracellular proteins have been identified as
TGM2 substrates (63). TGM2 acts at both intracellular and
extracellular levels (49), as TGM2 is localized at the cell-
surface, cytoplasmic, and nuclear levels. The intracellular
substrates of TGM2 noticeably include the transcription
factor NFkappaB, which is involved in breast cancer cell
growth and survival (64). TGM2 activates NFkappaB by
cross-linking and polymerizing the inhibitor of NFkappaB,
IkappaB, leading to its proteasomal degradation (64). In
addition, protein crosslinking is important for extracellular
matrix stabilization and while at the cell surface TGM2 in-
teracts with a variety of ECM proteins including integrins
(65) and fibronectin (66). Cell surface TGM2 is involved in
stabilizing tissues and in particular, lower TGM2 level leads
to less cross-linked collagen (67) that can be more effi-
ciently digested by metalloproteinases such as MMP1.
Thus, the strong up-regulation of MMP1 in 231-BR and the
down-regulation of TGM2 may synergistically contribute to
destabilizing the brain microenvironment and facilitate met-
astatic implantation and growth.
Another strongly down-regulated protein (by 26-fold) was
the calcium binding and metastasis-associated protein,
S100A4. It is well documented that S100A4 is expressed in
cancer cells and contributes to tumor cell motility and meta-
static progression, as well as angiogenesis (68). An important
characteristic feature of S100 proteins is their dual function,
inside and outside the cell, which may explain how it is able to
participate in a phenotype characteristic of cancer metasta-
sis. However, the exact underlying mechanisms remain unre-
solved (69). It is not known in this study whether the change in
S100A4 occurs at the intra- or extracellular level, or both, but
the strong decrease in 231-BR suggests a relationship to the
brain metastatic capability of breast cancer cells. In addition,
LCP1 (or L-plastin) was found down-regulated by more than
20-fold. This protein is an actin filament cross-linker that has
been shown to contribute to the fine-tuning of actin turnover
in breast cancer cells, and its phosphorylation by PKC-delta
has recently been shown to induce actin polymerization and
tumor cell invasion (72). The expression of LCP1 enhances
metastatic properties in both prostate cancer and melanoma
cells (73) and this study indicates a potential link with brain
metastasis as well.
CONCLUSION
This exploratory proteotranscriptomic study provides a
knowledgebase for better understanding the molecular mech-
anisms leading to brain metastasis and for delineating future
biomarkers and therapeutic targets of clinical interest. The
primary purpose of the study was to identify proteins regu-
lated in the human MDA-MB-231/231-BR model of brain me-
tastasis, which is unique because of its syngeneic nature. The
PRM analysis has been used as a further step to validate
the more dramatic changes observed in SILAC. In this regard,
the major up-regulated proteins (MMP1, EFNB1, STOM,
MYCT1) certainly represent the most valuable candidates for
further functional and clinical investigations by brain metas-
tasis specialized groups. However, the limitation of using a
single parent-descendent cell culture system dictates caution
in the interpretation of the results and suggests that a con-
servative approach toward describing broad applications is
appropriate. In future studies, xenografts may be used to
examine the proteome in the context of animal model to see
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if the cell line differences persist in the microenvironment. In
addition, functional investigations will have to be conducted
to evaluate the impact of the identified proteins in brain me-
tastasis and to define the clinical relevance. For instance
using shRNAi against the up-regulated proteins of interest (or
conversely overexpressing a down-regulated protein) in
231-BR could be used in functional brain metastasis assays.
However, there is no in vitro assay for brain metastasis, and in
vivo animal models have to be used as previously reported (7,
8). At the clinical level, it would be valuable to correlate the
expression of these proteins with the occurrence of brain
metastases and the survival of breast cancer patients. How-
ever, most data available, like in the Tumor Cancer Genome
Atlas (TCGA) (74), are at the gene/mRNA levels, and TCGA
breast cancer does not record brain metastasis. In this con-
text, proteogenomics, a globalized approach encompassing
gene/mRNA/protein levels together (75), represents a prom-
ising perspective. A first proteogenomic analysis of colon
cancer has recently been published (76) and the completion of
the same kind of study in breast cancer would provide a
powerful means to explore the functional and clinical involve-
ment of the proteins we describe here. Finally, the clinical
ramifications of this study may go beyond breast cancer.
Brain metastases commonly arise from primary cancers of the
lung and skin (melanoma), as well as at a lower frequency in
patients with other cancer types (1) and the candidate bio-
markers identified in this study could eventually be relevant
for brain metastases in other types of cancer. However, it is
impossible with only one cellular model to determine how
generalizable the observations will be, and this hypothesis will
have to be experimentally tested by investigating brain me-
tastasis models in other cancers.
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